BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 14, 2007
View Archived Issues
Isis Gets $45M Up Front In Deal With Ortho On Diabetes Drugs
Four months after licensing a preclinical, second-generation antisense drug for high cholesterol to Bristol-Myers Squibb Co. in a deal worth up to $192 million, Isis Pharmaceuticals Inc. is at it again. (BioWorld Today)
Read More
Genmab's 'Turnaround' Year Includes More Cancer Focus
Read More
More Is More For Receptor Tyrosine Kinase Inhibitors
Read More
PTC Gets $20M Investment From Celgene For Oncology Targets
Read More
Cell Therapy Company Aldagen Adds $9M To Series C Financing
Read More
Other News To Note
Read More
Clinic Roundup
Read More